vs

Side-by-side financial comparison of CITIZENS, INC. (CIA) and SOLENO THERAPEUTICS INC (SLNO). Click either name above to swap in a different company.

CITIZENS, INC. is the larger business by last-quarter revenue ($72.1M vs $66.0M, roughly 1.1× SOLENO THERAPEUTICS INC). SOLENO THERAPEUTICS INC runs the higher net margin — 39.4% vs 10.2%, a 29.2% gap on every dollar of revenue. SOLENO THERAPEUTICS INC produced more free cash flow last quarter ($43.5M vs $17.5M).

Citizen Watch Co., Ltd. , also known as the Citizen Group, is an electronics company primarily known for its watches and is the core company of a Japanese global corporate group based in Nishitokyo, Tokyo, Japan. In addition to Citizen brand watches, it is the parent of American watch company Bulova. Beyond watches, Citizen also manufactures calculators, printers, health care devices, and precision CNC machining equipment.

SOLENO THERAPEUTICS INC is a clinical-stage biopharmaceutical company specializing in developing novel therapies for rare endocrine, metabolic, and neurodevelopmental disorders. Its lead product candidate targets Prader-Willi syndrome, a rare genetic condition, with key patient markets across North America and the European Union.

CIA vs SLNO — Head-to-Head

Bigger by revenue
CIA
CIA
1.1× larger
CIA
$72.1M
$66.0M
SLNO
Higher net margin
SLNO
SLNO
29.2% more per $
SLNO
39.4%
10.2%
CIA
More free cash flow
SLNO
SLNO
$25.9M more FCF
SLNO
$43.5M
$17.5M
CIA

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
CIA
CIA
SLNO
SLNO
Revenue
$72.1M
$66.0M
Net Profit
$7.3M
$26.0M
Gross Margin
98.3%
Operating Margin
10.9%
33.5%
Net Margin
10.2%
39.4%
Revenue YoY
13.5%
Net Profit YoY
102.7%
134.0%
EPS (diluted)
$0.47

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CIA
CIA
SLNO
SLNO
Q4 25
$72.1M
Q3 25
$62.8M
$66.0M
Q2 25
$65.1M
$32.7M
Q1 25
$55.7M
Q4 24
$63.5M
Q3 24
$61.7M
Q2 24
$62.1M
Q1 24
$57.7M
Net Profit
CIA
CIA
SLNO
SLNO
Q4 25
$7.3M
Q3 25
$2.4M
$26.0M
Q2 25
$6.5M
$-4.7M
Q1 25
$-1.6M
Q4 24
$3.6M
Q3 24
$2.8M
Q2 24
$4.0M
Q1 24
$4.5M
Gross Margin
CIA
CIA
SLNO
SLNO
Q4 25
Q3 25
98.3%
Q2 25
97.9%
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
CIA
CIA
SLNO
SLNO
Q4 25
10.9%
Q3 25
7.1%
33.5%
Q2 25
10.6%
-20.0%
Q1 25
-3.2%
Q4 24
5.9%
Q3 24
4.9%
Q2 24
5.3%
Q1 24
8.5%
Net Margin
CIA
CIA
SLNO
SLNO
Q4 25
10.2%
Q3 25
3.8%
39.4%
Q2 25
9.9%
-14.4%
Q1 25
-2.9%
Q4 24
5.7%
Q3 24
4.5%
Q2 24
6.4%
Q1 24
7.9%
EPS (diluted)
CIA
CIA
SLNO
SLNO
Q4 25
Q3 25
$0.47
Q2 25
$-0.09
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CIA
CIA
SLNO
SLNO
Cash + ST InvestmentsLiquidity on hand
$23.0M
$498.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$235.0M
$494.8M
Total Assets
$1.8B
$599.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CIA
CIA
SLNO
SLNO
Q4 25
$23.0M
Q3 25
$23.1M
$498.9M
Q2 25
$22.7M
$286.8M
Q1 25
$18.4M
Q4 24
$29.3M
Q3 24
$32.4M
Q2 24
$26.3M
Q1 24
$23.2M
Stockholders' Equity
CIA
CIA
SLNO
SLNO
Q4 25
$235.0M
Q3 25
$225.6M
$494.8M
Q2 25
$229.0M
$240.1M
Q1 25
$218.1M
Q4 24
$210.4M
Q3 24
$207.6M
Q2 24
$191.5M
Q1 24
$195.2M
Total Assets
CIA
CIA
SLNO
SLNO
Q4 25
$1.8B
Q3 25
$1.7B
$599.9M
Q2 25
$1.7B
$332.3M
Q1 25
$1.7B
Q4 24
$1.7B
Q3 24
$1.7B
Q2 24
$1.7B
Q1 24
$1.7B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CIA
CIA
SLNO
SLNO
Operating Cash FlowLast quarter
$18.0M
$43.5M
Free Cash FlowOCF − Capex
$17.5M
$43.5M
FCF MarginFCF / Revenue
24.3%
65.8%
Capex IntensityCapex / Revenue
0.6%
0.0%
Cash ConversionOCF / Net Profit
2.45×
1.67×
TTM Free Cash FlowTrailing 4 quarters
$26.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CIA
CIA
SLNO
SLNO
Q4 25
$18.0M
Q3 25
$4.7M
$43.5M
Q2 25
$3.5M
$-12.6M
Q1 25
$748.0K
Q4 24
$31.9M
Q3 24
$9.7M
Q2 24
$4.6M
Q1 24
$6.8M
Free Cash Flow
CIA
CIA
SLNO
SLNO
Q4 25
$17.5M
Q3 25
$4.6M
$43.5M
Q2 25
$3.3M
$-12.6M
Q1 25
$641.0K
Q4 24
$31.3M
Q3 24
$9.3M
Q2 24
$4.5M
Q1 24
$6.7M
FCF Margin
CIA
CIA
SLNO
SLNO
Q4 25
24.3%
Q3 25
7.3%
65.8%
Q2 25
5.1%
-38.6%
Q1 25
1.2%
Q4 24
49.2%
Q3 24
15.1%
Q2 24
7.2%
Q1 24
11.7%
Capex Intensity
CIA
CIA
SLNO
SLNO
Q4 25
0.6%
Q3 25
0.1%
0.0%
Q2 25
0.3%
0.0%
Q1 25
0.2%
Q4 24
1.0%
Q3 24
0.6%
Q2 24
0.2%
Q1 24
0.1%
Cash Conversion
CIA
CIA
SLNO
SLNO
Q4 25
2.45×
Q3 25
1.93×
1.67×
Q2 25
0.54×
Q1 25
Q4 24
8.81×
Q3 24
3.48×
Q2 24
1.16×
Q1 24
1.49×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons